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Abstract
Objectives
To prospectively determine whether multi-parametric MRI (mpMRI) - contrast-enhanced
ultrasound (CEUS) correlated, imaging-guided target biopsy (TB) method could improve
the detection of prostate cancer in re-biopsy setting of patients with prior negative biopsy.
Methods
From 2012 to 2014, a total of 42 Korean men with a negative result from previous system-
atic biopsy (SB) and elevated prostate-specific antigen underwent 3T mpMRI and real-time
CEUS guided TB. Target lesions were determined by fusion of mpMRI and CEUS. Subse-
quently, 12-core SB was performed by a different radiologist. We compared core-based
cancer detection rates (CaDR) using the generalized linear mixed model (GLIMMIX) for
each biopsy method.
Results
Core-based CaDR was higher in TB (17.92%, 38 of 212 cores) than in SB (6.15%, 31 of 504
cores) (p < 0.0001; GLIMMIX). In the cancer-positive TB cores, CaDR with suspicious
lesions by mpMRI was higher than that by CEUS (86.8% vs. 60.5%, p= 0.02; paired t-test)
and concordant rate between mpMRI and CEUS was significantly different with discordant
rate (48% vs. 52%, p=0.04; McNemar’s test).
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Conclusion
The mpMRI-CEUS correlated TB technique for the repeat prostate biopsy of patients with
prior negative biopsy can improve CaDR based on the number of cores taken.
Introduction
Prostate cancer (PCa) is the second most common cancer and the sixth leading cause of can-
cer-related death in males worldwide [1, 2]. The 12-core transrectal ultrasound (TRUS)-guided
systematic biopsy (SB) is the standard and most common method for the detection of PCa.
However, the false negative rate of initial SB may be as high as 47% [3]. A repeat biopsy is fre-
quently required in patients with persisting clinical suspicion of PCa-after negative results
from a previous biopsy [4–6]. As the number of re-biopsy rounds increased, the detection rate
of PCa gradually decreased [7]. In an effort to improve the cancer detection and reduce false-
negative rates, investigators have explored alternative biopsy methods including targeted
biopsy (TB) under guidance (correlation) of multi-parametric magnetic resonance imaging
(mpMRI) [8]. Recently, mpMRI is widely used for the detection of PCa and has a good detec-
tion rate for local cancer lesions within the prostate gland [6, 9–11]. In addition, contrast-
enhanced ultrasound (CEUS) images of the prostate gland have shown better ability to detect
prostate cancer lesions than standard gray-scale TRUS. Several CEUS studies of the prostate
gland have suggested that adding TB to SB could improve cancer detection with a set number
of biopsy specimens instead of simply increasing the number of biopsy cores [12, 13].
Although highly sensitive and specific, in-bore MR-guided prostate biopsy is performed
selectively due to their procedure length, cost and discomfort to the patient. A potential solu-
tion to maximize the sensitivity is to acquire pre-biopsy diagnostic mpMRI and to correlate
them to the real-time CEUS images acquired during the TRUS-guided TB procedure. With
this protocol, the diagnostic power of prostate mpMRI could be fully coupled to the flexible
and rapid US-guided procedure.
The objective of our study is to evaluate prospectively the pre-acquired mpMRI-correlated,
real-time CEUS guided TB technique for the repeat prostate biopsy of patients with elevated
PSA levels. We hypothesized that the TB method will double the core-based detection rate of
the conventional SB method..
Materials and Methods
Patients
Patients who tested negative in a previous conventional 12-core TRUS-guided prostate biopsy
and were scheduled for repeated biopsies due to persistent suspicion of PCa based on a contin-
uously elevated serum PSA level (more than 4 ng/ml) were eligible for this study. Study enroll-
ment started in October 2012 and finished July 2014. Fifty-three patients agreed to participate,
but 5 were excluded for reasons stated in Fig 1. Thus 48 patients were enrolled, with 6 addi-
tional patients dropping out of the study (Fig 1.). The exclusion criteria were patients previ-
ously diagnosed with PCa, with a history of transurethral resection of prostate (TURP),
prostatectomy or radiation therapy to the pelvis for any other malignancy, or contraindication
to mpMRI or CEUS (pacemaker, magnetic implants, gadolinium-based MRI contrast allergy,
impaired renal function with glomerular filtration rate< 30 ml/min). Finally, 42 patients were
included prospectively, and this number was estimated according to the generalized linear
MpMRI-CEUS Guided Repeat Targeted Prostate Biopsy: A Prospective Study
PLOS ONE | DOI:10.1371/journal.pone.0130671 June 17, 2015 2 / 10
funded by the Ministry of Science, ICT & Future
Planning (grant number: NRF-2012R1A1A1042668).
Competing Interests: The authors have declared
that no competing interests exist.
mixed model (GLIMMIX) method for the statistical prediction of a meaningful number of
patients via statistical power analysis [14]. The detailed statistical modeling was summarized in
the S1 Table. Yonsei University Health System, Severance Hospital, Institutional Review Board
approved the entire study. Each patient signed the informed consent.
Multi-parametric MR imaging
To identify suspected PCa lesions, patients underwent mpMRI using a 3T MR scanner (Sie-
mens, Trio Tim, Erlangen, Germany) without endorectal coil after injection of MR contrast
media, Gadoterate meglumine (Dotarem, Guerbet, Roissy CdG, France) (Table 1). MR imaging
was performed at least six months after any previous biopsy, to avoid the post-biopsy hemor-
rhage of the prostate. Images were reviewed by a specialized radiologist with ten years of expe-
rience in prostate mpMRI using the validated Prostate Imaging Reporting and Data System
(PI-RADS) [15–17]. After reviewing the mpMRI, the radiologist chose candidates among
equivocal (PI-RADS 3) or intermediate/high-risk (PI-RADS 4/5) lesions on mpMRI and
ranked them depending on the scores. If any cases had multiple suspicious lesions on review,
we limited these to less than 3.
Fig 1. Flow chart of the patient enrollment.
doi:10.1371/journal.pone.0130671.g001
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Contrast-enhanced US (CEUS) imaging and biopsy
Within one week after imaging by mpMRI, transrectal CEUS was performed on each patient.
The contrast agent SonoVue (Bracco, Milan, Italy) was used in conjunction with a Siemens
S2000 US system (Siemens Medical Solution, Mountain View, CA, USA) in a contrast-specific
imaging mode called Cadence contrast pulse sequencing (CPS) technology (Siemens Medical
Solution, Mountain View, CA, USA) (S2 Table). If there was a suspected lesion on first bolus of
SonoVue, the CEUS-based suspicious lesions were compared with the lesions already selected
on mpMRI by the radiologist who reviewed the mpMRI and performed transrectal CEUS
simultaneously [19]. The target sites were decided by taking into account both mpMRI and
CEUS images. And then a repeated bolus was used for exact targeting. We targeted suspicious
lesions subjectively during first round real-time CEUS and confirmed that lesion in a second
CEUS after 3 to 5 minutes from the 1st injection.
TB for PCa was performed as follows: first, correlated lesions on both mpMRI and CEUS
were targeted (Fig 2.); second, CEUS-only positive lesions were targeted; finally, mpMRI-only
suspicious lesions were taken by TB under TRUS guidance. If multiple lesions were detected,
we also performed TB on each lesion a total of not more than six times. If there was no suspi-
cious lesion on both images, an additional six randomized biopsies were performed in both
transitional zones and peripheral zones. After TB, conventional TRUS-guided 12-core SB was
performed using an extended sextant biopsy scheme by a different radiologist (YTO) who was
unaware of the mpMRI/CEUS findings [20]. All biopsies were performed using an 18-gauge
spring-loaded Acecut biopsy gun (TSK Laboratories, Nagoya, Japan). All biopsy cores were
coded with number and group (TB or SB) and sent for pathologic examination. Biopsy cores
were reviewed by one of the cytopathologists specializing in the genitourinary system and
reported either as cancer with an assigned Gleason score or as benign prostatic tissue.
Statistical analysis
The prostate cancer detection rate (CaDR) based on core numbers was calculated in addition
to the overall patient number-based CaDR. We compared the core-based detection rate of each
biopsy method (TB versus SB) using GLIMMIX with correlated binary outcomes in this
Table 1. MR protocol of multiparametric MRI of the prostate who underwent contrast-enhanced US
guided biopsy.
1. T2WI axial, coronal, sagittal: TR, 3800 msec; TE, 98 msec; slice thickness, 4 mm; 448 x 314 matrix;
FOV, 150x150 mm.
2. T1WI axial, before contrast material injection: TR, 700 msec; TE, 11 msec; slice thickness, 5 mm; 320
x 288 matrix; FOV, 160x160 mm.
3. DWI axial with a single-shot-echo-planar imaging: b-values of 0, and 1000 s/mm2; TR, 4400 msec; TE,
86 msec; slice thickness; 4 mm; 192 x 192 matrix; FOV, 240x240 mm.. ADC maps were automatically
calculated by the scanner software.
4. DCE T1WI axial during an intravenous injection of gadolinium-based contrast material at 0.1 mmol/kg:
TR, 3.44 msec; TE, 1.19 msec; thickness, 2 mm; matrix, 320×192; FOV, 360x252 mm. The Ktrans
map for each voxel was ﬁnally overlapped over T2-weighted images*.
T1WI and T2WI = T1- and T2-weighted images, TR = repetition time, TE = echo time, msec = millisecond,
FOV = ﬁeld of view, DWI = diffusion weighted images, ADC = apparent diffusion coefﬁcient,
DCE = dynamic contrast enhanced, Ktrans = transfer constant.
* The ﬁtting of concentration versus time curves was performed based on theoretical models by Tofts.
Perfusion-related parameters including Ktrans were derived by the curves [18]. We used commercial
software (Tissue4D; Siemens healthcare, Erlangen, Germany) in the construction of perfusion map images.
doi:10.1371/journal.pone.0130671.t001
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clustered data. To determine whether differences in the Gleason score between SB and TB were
significant, the Wilcoxon’s signed-rank test was performed. In the analysis of cancer-positive
TB cores, we performed McNemar’s test between mpMRI and CEUS findings in each cores.
All reported P values are one-sided, and a significant level of 5% was used. All analyses were
conducted using MedCalc software for Windows (MedCalc Software version 12.7.5, Maria-
kerke, Belgium) and SPSS 20.0 (released 2011, IBM statistics for Windows version 20, IBM
Corp., Armonk, NY) for GLIMMIX analysis.
Results
Table 2 lists summary statistics relating to the patients. Overall, PCa was detected in 18 of 42
patients (42.9%). Fourteen of 18 patients (77.8%) with PCa had clinically significant cancer
(Gleason>6 or Gleason 6 with>50% PCa per core or>2 cores PCa) [21]. Fifteen patients
with PCa (83.4%) had predominant Gleason 3 architecture (Gleason 3 + 3 or 3 + 4). The results
Fig 2. Prostate cancer in a 73-year-old man with a PSA level of 12.3 ng/mL and a history of a negative biopsy findings. A. Axial T2-weighted image in
a 71-year-old man with prostate cancer in the left TZ shows homogeneous low signal intensity, ill-defined margins, and lack of a hypointense capsule (arrow).
B. Corresponding ADCmap shows restricted diffusion as area of low signal intensity (arrow). C. Axial perfusion map shows focal enhancement in left TZ
(arrow). D. Time intensity curve shows red, type 3 enhancement curve (red circle: cancer focus). Green curve is type 1 enhancement pattern (green circle:
normal tissue). E. Axial transrectal US image acquired after contrast material injection shows the corresponding an asymmetric early wash-in area on
contrast pulse sequence–mode images (outlined by asterisks). Biopsy was performed targeting this area, and we were able to confirm the presence of
cancer. Histopathologic examination indicated a prostate carcinoma with a Gleason score of 6 (3+3) at targeted biopsy (TB) only.
doi:10.1371/journal.pone.0130671.g002
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of the patient-based CaDR are summarized in Table 3. The mean number of all biopsy cores
per participant was 17.8 (Range: 15–18).
CaDR based on biopsy cores are summarized in Table 4. A total of 212 TB cores and 504 SB
cores was obtained from 42 patients. CaDR was significantly (p< 0.0001; GLIMMIX) higher
in the TB cores (17.92%, 38 of 212 cores) than in the SB cores (6.15%, 31 of 504 cores). The
Gleason score detected by the two techniques was not significantly different (P = 0.84; Wil-
coxon signed-rank test). In the analysis of cancer-positive TB cores (Table 5), CaDR with sus-
picious lesions by mpMRI (PI-RADS 3/4/5) was much higher (86.8%, 33 of 38 cores) than that
by CEUS (60.5%, 23 of 38 cores). Five discordant cores, however, revealed CEUS positive and
mpMRI negative finding. And, concordant rate between mpMRI and CEUS was not signifi-
cantly different with discordant rate (48% vs. 52%, p>0.01).
Table 2. Patient demographics of the real-time contrast enhanced ultrasound guided biopsy.
All Subjects(n = 42)* PCa proven(n = 18)*
Age, year (mean±SD) 62.7±10.0 65.8±6.69
Median (range) 65(28 ~ 77) 68(54 ~76)
PSA(ng/mL)
Median (range) 9.77 (4.3 ~ 99.1) 8.76 (4.3 ~ 99.1)
4–9.9 22 (52.4%) 11(61.1%)
More than 10 20 (47.6%) 7 (38.9%)
Prostate volume (mL) 44.01±20.99 33.96±11.77
Median(range) 39.5(12.5 ~ 88.7) 32.6(12.5 ~ 51.0)
< 30 cc 13 (31.0%) 8 (44.4%)
> = 30 cc 29 (69.0%) 10 (55.6%)
DRE
Normal 15 (35.7%) 7 (38.9%)
Abnormal 27 (40.5%) 11 (61.1%)
mpMRI score
PI-RADS 1/2 9 0
PI-RADS 3 14 5
PI-RADS 4/5 19 13
CEUS ﬁndings
CEUS negative 10 3
CEUS positive 32 15
PCa = Prostate cancer; PSA = Prostate speciﬁc antigen; DRE = digital rectal examination;
mpMRI = multiparametric Magnetic resonance imaging; PI-RADS = Prostate Imaging Reporting and Data
System; CEUS = contrast enhanced ultrasound;
* No. of patients
doi:10.1371/journal.pone.0130671.t002
Table 3. Patient based comparison of cancer detection rate between systematic biopsy group and tar-
geted biopsy group.
Target biopsy
Systematic biopsy Negative Positive Total (%)
Negative 24 5 29 (69.0)
Positive 5 8 13 (31.0)
Total (%) 29 (69.0) 13 (31.0) 42
doi:10.1371/journal.pone.0130671.t003
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Discussion
We performed cognitive fusion between mpMRI and CEUS, which was simple, quick and
required no additional equipment beyond the MRI and a CEUS facility. This method may
overcome the disadvantage of simple cognitive fusion using conventional T2WI and ultra-
sound because perfusion mapping derived from DCE-MRI and real time CEUS images offers
additional similar perfusion information in prostate tissues and is helpful in the detection and
real-time registration of focal hypervascular lesions so that lesions can be targeted more pre-
cisely. The increase in microvessels in prostate cancer enables CEUS to improve vascular imag-
ing and resolution [22]. By adding CEUS for TB, diagnostic performance, especially sensitivity,
increases. Tumors located at the peripheral zone, with higher Gleason score and larger size, are
more likely to become markedly enhanced [23]. Although CEUS improves PCa detection in
rebiopsy setting, the sensitivity of CEUS-only biopsy is reduced in small, low-grade tumors,
centrally located lesions and large infiltrating prostate tumors [24]. In addition, CEUS-com-
bined TRUS guided targeted biopsy in previous years has not considered clinically useful [25].
After TB for MR-CEUS correlated lesions, additional TB cores were taken from discrepant
lesions, mpMRI positive and CEUS negative lesions, or vice versa. Hence, this method could
cover lesions from standard cognitive fusion biopsy (MRI-TRUS) as well as lesions hidden
Table 4. Core based comparison of cancer detection between systematic biopsy group and targeted
biopsy group.
TB (%) SB (%) P (95 C.I)
ALL 17.92 (38/212)* 6.15 (31/504)* < 0.0001(4.554~15.105)
PIRADS 3/4/5 28.44 (33/116)* n/a
PIRADS 1/2 5.21 (5/96)* n/a
CEUS positive 18.11 (23/127)* n/a
CEUS negative 17.64 (15/85)* n/a
Gleason sum(n, %)
Benign 174 (82.1) 473 (93.8)
GS 6 23 (10.9) 27(5.4)
GS 7 7 (3.3) 2(0.4)
GS 8–10 8 (3.7) 2(0.4)
TB = Target biopsy; SB = Systematic biopsy; PI-RADS = Prostate Imaging Reporting and Data System; n/
a = not applicable; CEUS = contrast enhanced ultrasound
* Positive/Total cores (cancer detection rates)
doi:10.1371/journal.pone.0130671.t004
Table 5. Agreement betweenmpMRI and CEUS in positive TB cores (Numbers of cores containing
cancer detected by targeted biopsy).
mpMRI
CEUS Negative(PIRADS 1/2) Positive(PIRADS 3/4/5) Total (%)
Negative 0 15 15 (39.5)
Positive 5 18 23 (60.5)
Total (%) 5 (13.2) 33 (86.8) 38
CEUS = contrast enhanced ultrasound; mpMRI = multi-parametric MRI; TB = Target biopsy;
PI-RADS = Prostate Imaging Reporting and Data System
doi:10.1371/journal.pone.0130671.t005
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from CEUS or mpMRI. In addition, we could have another chance at detecting cancerous tis-
sue which appear a ‘normal’ on mpMRI; however, this could still be problematic, as false-
negative aspects of prostate MRI are not yet known. Among discrepant lesions between
mpMRI and CEUS, mpMRI-only positive cores showed markedly higher detection rate than
CEUS-only positive cores. This result indicates that we can increase the prostate CaDR by tar-
geting suspicious lesions with a bias toward pre-biopsy mpMRI over CEUS. In addition, we
found that the 15 mpMRI-only positive cores were mainly located in anterior portion of transi-
tional zone and anterior fibromuscular stroma (60%, 9/15), which were consistent with those
of a previous study by Pepe et al [26]. Our mpMRI-CEUS-correlated TB showed an improved
CaDR with fewer cores than SB; thus, this method may be comparable to saturation biopsy
techniques with a higher number of samples (20 cores; CaDR, 25%–41%) [27–29]. Also,
MR-CEUS guided biopsy method with cognitive correlation was significantly more cost-
effective than the inbore-MR guided biopsy, since the patient pays extra for the contrast agent
instead of the inbore-MR biopsy equipment.
There was a technical limitation of CEUS. Because of a limited temporal window of CEUS
for scanning entire prostate, biopsy had to be performed in very short time duration. As the
prostate was larger, we had less of a chance to observe the enhancing pattern of the entire pros-
tate. Follow up TB or SB will be planned in patients who were negative in this study. Since we
carried out an extended biopsy (12 cores) in the control group instead of saturation biopsy, we
could not perform a comparison between TB and saturation biopsy. Two of 5 patients who
have missed PCa on TB cores were clinically significant.
We initially hypothesized for detection rate to be twice by using this multi-modality-
correlated, imaging-guided TB technique. We achieved the improvement in CaDR based on
the number of cores taken. In conclusion, the mpMRI-CEUS-correlated imaging-guided TB
technique for the repeat prostate biopsy of patients with suspected PCa can be used to improve
diagnostic accuracy.
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